| Phase 12 trials |
|
Phase 1
|
NCT05293496 |
Apr 2022 → Jun 2025 |
castration-resistant prostate carcinoma, hepatocellular carcinoma, malignant epithelial tumor of ovary, melanoma +2 |
MacroGenics |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03761017 |
Dec 2018 → Aug 2024 |
colorectal cancer, cutaneous melanoma, metastatic prostate carcinoma, non-small cell squamous lung carcinoma |
MacroGenics |
Completed
|
No outcome recorded
|
| Phase 1/21 trial |
|
Phase 1/2
|
NCT07137390 |
Sep 2025 → Jan 2026 |
colorectal cancer |
M.D. Anderson Cancer Center |
Withdrawn
|
No outcome recorded
|
| Phase 26 trials |
|
Phase 2
|
NCT07565155 |
Jun 2026 → Jun 2031 expected |
pancreatic ductal adenocarcinoma |
Peter Hosein, MD |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07071961 |
Feb 2026 → May 2027 |
colorectal cancer |
M.D. Anderson Cancer Center |
Suspended
|
No outcome recorded
|
|
Phase 2
|
NCT07223567 |
Oct 2025 → Jan 2026 |
rectal cancer |
M.D. Anderson Cancer Center |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT06730347 |
May 2025 → Jul 2027 expected |
cervical clear cell adenocarcinoma, endometrial cancer, fallopian tube clear cell adenocarcinoma, ovarian clear cell adenocarcinoma +3 |
MacroGenics |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05848011 |
Sep 2023 → Feb 2026 |
hormone-resistant prostate carcinoma |
MacroGenics |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT05475171 |
Dec 2022 → Jun 2028 |
cervical cancer, metastatic malignant neoplasm |
M.D. Anderson Cancer Center |
Suspended
|
No outcome recorded
|